A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors.

Kiyohiro AndoKazuyuki HamadaMidori ShidaRyotaro OhkumaYutaro KubotaAtsushi HoriikeHiroto MatsuiTomoyuki IshiguroYuya HirasawaHirotsugu AriizumiMakoto WatanabeRie OnoueJunji TsurutaniKiyoshi YoshimuraTakuya TsunodaShinichi KobayashiSatoshi Wada

Published in: Cancer immunology, immunotherapy : CII (2020)

Increase in pretreatment expression levels of PD-L1 on CD14+ monocytes is associated with the OS of patients treated with immune checkpoint inhibitors. Further evaluation of large sample size and each specific cancer type might clarify the predictive role of PBMC in patients.

Keyphrases

peripheral blood
end stage renal disease
ejection fraction
poor prognosis
chronic kidney disease
dendritic cells
papillary thyroid
peritoneal dialysis
prognostic factors
patient reported outcomes
squamous cell carcinoma
immune response
nk cells
patient reported